The extension brings total Series C financing to £18.8m with participation from US investor Modi Ventures.
"This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments."
The British Business Bank contributed £5m to the £30m financing alongside several new and existing backers.
"SatVu has created a unique technology at a time of great demand for defence innovation. They have proved the strategic value of their technology so we are pleased to provide the funding that will help them to scale and win further contracts."
The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.
"Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process."
